TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Westminster, CO, US. The stock last traded at $5.71, down 0.52% on the session, giving a market capitalisation of $351.6M. On trailing twelve-month figures it carries a trailing P/E of -4.39, a net margin of -62.6%. Its beta of 0.43 implies it has historically moved less than the broad market.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. is most often compared with the following Healthcare names: